FIGURE LEGENDS
FIG 1 Comparison of daily urinary biomarker measurements
between treatment groups and across dosing days. (a) Urinary output.
Values expressed as mean ± SD; * vancomycin vs saline, #
vancomycin+flucloxacillin vs saline, @ vancomycin+flucloxacillin vs
vancomycin. Total amounts of urinary KIM-1 (b), clusterin (c), and OPN
(d) in saline (n=11), flucloxacillin (n=6), vancomycin (n=12),
vancomycin+flucloxacillin (n=10) and vancomycin+imipenem-cilastatin
(n=6)-treated rats. Values expressed as median (min-max); * vs
vancomycin. KIM-1, kidney injury molecule-1; OPN, osteopontin.
FIG 2 Vancomycin concentration in the kidney tissue. Values
expressed as median and interquartile range.
FIG 3 Correlation between urinary KIM-1 (ng/24 h) and
vancomycin in the kidney (µg/g).
FIG 1 Comparison of daily urinary biomarker measurements
between treatment groups and across dosing days. (a) Urinary output.
Values expressed as mean ± SD; * vancomycin vs saline, #
vancomycin+flucloxacillin vs saline, @ vancomycin+flucloxacillin vs
vancomycin. Total amounts of urinary KIM-1 (b), clusterin (c), and OPN
(d) in saline (n=11), flucloxacillin (n=6), vancomycin (n=12),
vancomycin+flucloxacillin (n=10) and vancomycin+imipenem-cilastatin
(n=6)-treated rats. Values expressed as median (min-max); * vs
vancomycin. KIM-1, kidney injury molecule-1; OPN, osteopontin.